These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1678921)

  • 1. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
    Deger G
    Am J Med; 1986 May; 80(5B):62-7. PubMed ID: 2872809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
    Achari R; Hosmane B; Linnen P; Cavanaugh J; Baroldi P; Cohen A
    J Clin Pharmacol; 1998 Jun; 38(6):545-53. PubMed ID: 9650545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
    Pool JL
    Am Heart J; 1991 Sep; 122(3 Pt 2):926-31. PubMed ID: 1678924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with terazosin administered in combination with other antihypertensive agents.
    Chrysant SG
    Am J Med; 1986 May; 80(5B):55-61. PubMed ID: 2872808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative trials of terazosin with other antihypertensive agents.
    Ruoff G
    Am J Med; 1986 May; 80(5B):42-8. PubMed ID: 2872806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
    Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
    Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of terazosin as an antihypertensive agent.
    Luther RR; Glassman HN; Jordan DC; Sperzel WD
    Am J Med; 1986 May; 80(5B):73-6. PubMed ID: 2872811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
    Cohen JD
    Am Heart J; 1991 Sep; 122(3 Pt 2):919-25. PubMed ID: 1678923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of terazosine and atenolol on serum lipids in essential hypertension].
    Bur A; Woisetschläger C; Herkner H; Derhaschnig U; Quehenberger P; Hirschl MM
    Z Kardiol; 2002 Sep; 91(9):685-92. PubMed ID: 12448067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
    Dauer AD
    Am J Med; 1986 May; 80(5B):29-34. PubMed ID: 2872804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR; Glassman HN; Sperzel WD; Steinberg FJ; Horton JK; Jordan DC
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term experience with terazosin for treatment of mild to moderate hypertension.
    Mersey JH
    Am J Med; 1986 May; 80(5B):68-72. PubMed ID: 2872810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
    Silke B; Guy S; Humphreys JE
    J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of terazosin.
    Cohen J
    J Clin Pharmacol; 1993 Mar; 33(3):272-8. PubMed ID: 8096524
    [No Abstract]   [Full Text] [Related]  

  • 19. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
    Kirby RS
    Br J Urol; 1998 Sep; 82(3):373-9. PubMed ID: 9772873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.